Nedaplatin
Nedaplatin Basic information
- Product Name:
- Nedaplatin
- Synonyms:
-
- (glycolato-o,o')diammineplatinum(ii)
- cis-diammine(glycolato)platinum(ii)
- NEDAPLATIN
- 254-s
- Aqupla
- cis-diamine-glycolate-O,O'-platinum(II)
- o(sup2))-diammine(hydroxyacetato(2-)-o(sup1(sp-4-3)-platinu
- Nedaplait
- CAS:
- 95734-82-0
- MF:
- C2H6N2O3Pt
- MW:
- 301.17
- Product Categories:
-
- Inhibitors
- Anticancer
- Anticancer Platinum Agent
- Mol File:
- 95734-82-0.mol
Nedaplatin Chemical Properties
- storage temp.
- Inert atmosphere,Store in freezer, under -20°C
- solubility
- H2O : 13.6 mg/mL (44.86 mM; Need ultrasonic and warming; DMSO can inactivate Nedaplatin's activity)DMF : < 1 mg/mL (insoluble; DMSO can inactivate Nedaplatin's activity)
- form
- Powder
Nedaplatin Usage And Synthesis
Description
Nedaplatin, a novel second generation platinum complex, was marketed in Japan for the treatment of a variety of cancers including: head and neck, small-cell and non-small cell lung, oesophageal, prostatic, testicular, ovarian, cervical, bladder, and uterine cancers. Platinum anticancer agents, prototyped by cisplatin, have been reported to be hydrolyzed to the mono- or diaquated species of diamine platinum which react with nucleophilic sites on DNA to cause intrastrand and interstrand crosslinks and DNA-protein crosslinks, which result in cytotoxicity. Nedaplatin was reportedly more active than cisplatin against several solid tumors while sharing less nephro- and gastrointestinal toxicity to cisplatin in viva The minimal renal toxicity displayed by nedaplatin allows its use in patients with deteriorated renal function.
Originator
Shionogi (Japan)
Uses
anticancer
Uses
Nedaplatin is a platinum complex that has potent antineoplatic activity.
brand name
Aqupla
Pharmaceutical Applications
Nedaplatin, cis-diammineglycolatoplatinum(II), is structurally similar to carboplatin. The chemical structure consists of a central platinum(II) atom with two cis-ammonia groups as nonleaving groups and – in contrast to carboplatin – the dianionic form of glycolic acid as the leaving group. Nedaplatin has been approved for the clinical use in the Japanese market for the treatment of head and neck, testicular, ovarian, lung and cervical cancer. It is typically administered by IV injection and its dose-limiting side effect is myelosuppression.
NedaplatinSupplier
- Tel
- 010-82848833 400-666-7788
- jkinfo@jkchemical.com
- Tel
- 821-50328103-801 18930552037
- 3bsc@sina.com
- Tel
- 021-20908456
- sales@BioChemBest.com
- Tel
- 0757-86329057 18501085097
- sales3.gd@hwrkchemical.com
- Tel
- 86-027-67849912
- sales@chemwish.com